Literature DB >> 22334233

Emerging significance of estrogen cancer coregulator signaling in breast cancer.

M Mann1, S Krishnan, R K Vadlamudi.   

Abstract

Estrogen receptor (ERα) plays an important role in the initiation and progression of breast cancer. Many breast cancer patients respond positively to hormonal therapy; however, initial or acquired resistance to endocrine therapies frequently occurs and tumors recur as metastases. Emerging evidence suggests that ERα action is complex and involves functional interactions with coregulators. The levels of ERα coregulator proteins are tightly regulated under normal conditions and ERα-coregulator proteins have the potential to be differentially expressed in malignant tumors and have altered functions leading to tumor progression and metastases. In this review, we summarize recent findings that relate to ERα coregulators and discuss implications of ERα coregulator deregulation in breast cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22334233

Source DB:  PubMed          Journal:  Minerva Ginecol        ISSN: 0026-4784


  8 in total

Review 1.  PELP1: a key mediator of oestrogen signalling and actions in the brain.

Authors:  R Thakkar; G R Sareddy; Q Zhang; R Wang; R K Vadlamudi; D Brann
Journal:  J Neuroendocrinol       Date:  2018-02       Impact factor: 3.627

2.  PTHGRN: unraveling post-translational hierarchical gene regulatory networks using PPI, ChIP-seq and gene expression data.

Authors:  Daogang Guan; Jiaofang Shao; Zhongying Zhao; Panwen Wang; Jing Qin; Youping Deng; Kenneth R Boheler; Junwen Wang; Bin Yan
Journal:  Nucleic Acids Res       Date:  2014-05-29       Impact factor: 16.971

Review 3.  Derailed estrogen signaling and breast cancer: an authentic couple.

Authors:  Bramanandam Manavathi; Oindrilla Dey; Vijay Narsihma Reddy Gajulapalli; Raghavendra Singh Bhatia; Suresh Bugide; Rakesh Kumar
Journal:  Endocr Rev       Date:  2012-09-04       Impact factor: 19.871

4.  Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy.

Authors:  Zhuan Zhou; Joe X Qiao; Amit Shetty; George Wu; Yi Huang; Nancy E Davidson; Yong Wan
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.207

5.  HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL.

Authors:  Xuehai Bian; Zhongxing Liang; Amber Feng; Eric Salgado; Hyunsuk Shim
Journal:  Biochem Pharmacol       Date:  2017-12-01       Impact factor: 6.100

6.  Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.

Authors:  S S Roy; V K Gonugunta; A Bandyopadhyay; M K Rao; G J Goodall; L-Z Sun; R R Tekmal; R K Vadlamudi
Journal:  Oncogene       Date:  2013-08-26       Impact factor: 9.867

7.  An integrative method to decode regulatory logics in gene transcription.

Authors:  Bin Yan; Daogang Guan; Chao Wang; Junwen Wang; Bing He; Jing Qin; Kenneth R Boheler; Aiping Lu; Ge Zhang; Hailong Zhu
Journal:  Nat Commun       Date:  2017-10-19       Impact factor: 14.919

8.  A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.

Authors:  Jae Yong Lee; Young Joon Park; Nuri Oh; Kyu Bum Kwack; Kyung-Soon Park
Journal:  Oncotarget       Date:  2017-06-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.